Glioblastoma Multiforme

Oncology
29
Pipeline Programs
20
Companies
39
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
9
8
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Vaccine
133%
+ 28 programs with unclassified modality

Competitive Landscape

20 companies ranked by most advanced pipeline stage

Precision BioSciences
3 programs
1
1
1
ICT-107Phase 31 trial
ICT-107Phase 21 trial
ICT-121 DC vaccinePhase 1Vaccine1 trial
Active Trials
NCT02049489Completed20Est. Mar 2017
NCT01280552Completed124Est. Dec 2015
NCT02546102Suspended234Est. Dec 2025
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
Steroid eye dropsPhase 31 trial
ABT-414Phase 11 trial
Active Trials
NCT01800695Completed202Est. Jun 2017
NCT03419403Terminated40Est. Mar 2020
E
EisaiChina - Liaoning
3 programs
1
1
GliadelPhase 21 trial
BCNU WaferPhase 1/21 trial
MRS SpectroscopyN/A1 trial
Active Trials
NCT00645385Withdrawn0Est. Jun 2011
NCT00984438Withdrawn0Est. Jun 2010
NCT01186406Terminated41Est. Jun 2014
Genentech
GenentechCA - Oceanside
2 programs
1
1
GliadelPhase 2
BevacizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT01091792Completed13Est. Apr 2015
Teva
TevaIsrael - Petach Tikva
2 programs
2
TalampanelPhase 24 trials
TalampanelPhase 21 trial
Active Trials
NCT00964730Completed135Est. Feb 2010
NCT00036296Completed22Est. Feb 2007
NCT00062504Terminated30Est. Apr 2006
+2 more trials
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 102Phase 21 trial
Active Trials
NCT01113398Completed36Est. Sep 2015
M&
Merck & Co.RAHWAY, NJ
1 program
1
BirabresibPhase 21 trial
Active Trials
NCT02296476TerminatedEst. Oct 2015
Lassen Therapeutics
Lassen TherapeuticsCA - San Diego
1 program
1
bevacizumab and Irinotecan and radiotherapyPhase 21 trial
Active Trials
NCT00817284CompletedEst. Nov 2011
Novartis
NovartisBASEL, Switzerland
3 programs
2
1
AEE788Phase 1/21 trial
68Ga-FF58Phase 11 trial
MBG453Phase 11 trial
Active Trials
NCT04712721Terminated14Est. Jul 2024
NCT03961971Active Not Recruiting16Est. Sep 2026
NCT00116376Completed64Est. Nov 2005
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
2
BIBF 1120Phase 1/21 trial
CetuximabPhase 1/2Monoclonal Antibody2 trials
Active Trials
NCT01666600Terminated63Est. Sep 2017
NCT00311857Unknown46
NCT00115518Completed30Est. Aug 2010
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
CYT997Phase 1/21 trial
CYT997Phase 1/2
Active Trials
NCT00650949Terminated20Est. Jun 2011
Karyopharm Therapeutics
1 program
1
SelinexorPhase 1/21 trial
Active Trials
NCT04421378TerminatedEst. Jul 2023
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
TemozolomidePhase 1/25 trials
Active Trials
NCT05106296Recruiting37Est. Sep 2028
NCT04514393Unknown33Est. Jun 2024
NCT03899155Recruiting1,500Est. Aug 2029
+2 more trials
VBI Vaccines
VBI VaccinesMA - Cambridge
1 program
1
VBI-1901Phase 1/21 trial
Active Trials
NCT03382977RecruitingEst. Aug 2025
Pyxis Oncology
Pyxis OncologyBOSTON, MA
1 program
1
APX005M treatment for recurrent or refractory primary malignant CNS tumor patientsPhase 11 trial
Active Trials
NCT03389802Active Not RecruitingEst. Jun 2026
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD2014Phase 11 trial
Active Trials
NCT02619864Completed15Est. Feb 2020
Erasca
ErascaSAN DIEGO, CA
1 program
1
ERAS-801Phase 11 trial
Active Trials
NCT05222802Active Not RecruitingEst. Sep 2025
AM-Pharma
AM-PharmaNetherlands - Utrecht
1 program
1
Ex-Vivo expanded autologous IL-8 receptorPhase 11 trial
Active Trials
NCT05353530RecruitingEst. Dec 2042
Biogen
BiogenCAMBRIDGE, MA
1 program
1
Interferon-betaPhase 12 trials
Active Trials
NCT00299962Completed17Est. Oct 2009
NCT00031083Completed12Est. Oct 2003
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
KHK2455N/A1 trial
Active Trials
NCT04321694No Longer Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Precision BioSciencesICT-107
AbbVieSteroid eye drops
Johnson & JohnsonTemozolomide
Johnson & JohnsonTemozolomide
Johnson & JohnsonTemozolomide
Merck & Co.Birabresib
EisaiGliadel
Precision BioSciencesICT-107
AmgenAMG 102
Lassen Therapeuticsbevacizumab and Irinotecan and radiotherapy
TevaTalampanel
Heidelberg PharmaCetuximab
TevaTalampanel
TevaTalampanel
Karyopharm TherapeuticsSelinexor

Showing 15 of 38 trials with date data

Clinical Trials (39)

Total enrollment: 3,247 patients across 39 trials

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Start: Dec 2024Est. completion: Dec 2025234 patients
Phase 3Suspended
NCT03419403AbbVieSteroid eye drops

UNITE Study: Understanding New Interventions With GBM ThErapy

Start: Jul 2018Est. completion: Mar 202040 patients
Phase 3Terminated

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Start: Oct 2020Est. completion: Jun 202433 patients
Phase 2Unknown

Pan Tumor Rollover Study

Start: May 2020Est. completion: Aug 20291,500 patients
Phase 2Recruiting

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Start: Oct 2019Est. completion: Oct 2027130 patients
Phase 2Active Not Recruiting

A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

Start: Oct 2014Est. completion: Oct 2015
Phase 2Terminated

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Start: Apr 2011Est. completion: Jun 201441 patients
Phase 2Terminated

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Start: Jan 2011Est. completion: Dec 2015124 patients
Phase 2Completed

AMG 102 and Avastin for Recurrent Malignant Glioma

Start: Aug 2010Est. completion: Sep 201536 patients
Phase 2Completed
NCT00817284Lassen Therapeuticsbevacizumab and Irinotecan and radiotherapy

Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

Start: Nov 2008Est. completion: Nov 2011
Phase 2Completed
NCT00267592TevaTalampanel

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Start: Dec 2005Est. completion: Feb 201172 patients
Phase 2Completed

Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Start: May 2005Est. completion: Aug 201030 patients
Phase 2Completed
NCT00062504TevaTalampanel

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Start: Jul 2003Est. completion: Apr 200630 patients
Phase 2Terminated
NCT00034814TevaTalampanel

Multicenter Trial for Adults With Partial Seizures

Start: Jan 2002Est. completion: Jan 2006190 patients
Phase 2Completed

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Start: Jun 2020Est. completion: Jul 2023
Phase 1/2Terminated

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Start: Dec 2017Est. completion: Aug 2025
Phase 1/2Recruiting

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Start: Oct 2013Est. completion: Apr 202436 patients
Phase 1/2Completed

NOA-12: BIBF1120 and R-RT in Glioblastoma

Start: Aug 2012Est. completion: Sep 201763 patients
Phase 1/2Terminated

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

Start: Nov 2009Est. completion: Jun 201120 patients
Phase 1/2Terminated

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

Start: Jun 2009Est. completion: Jun 20100
Phase 1/2Withdrawn
NCT00036296TevaTalampanel

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Start: Dec 2006Est. completion: Feb 200722 patients
Phase 1/2Completed

Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

Start: Feb 200646 patients
Phase 1/2Unknown

Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

Start: Jan 2004Est. completion: Nov 200564 patients
Phase 1/2Completed

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

Start: Dec 2002Est. completion: Oct 200855 patients
Phase 1/2Completed
NCT05353530AM-PharmaEx-Vivo expanded autologous IL-8 receptor

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

Start: Jul 2023Est. completion: Dec 2042
Phase 1Recruiting

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Start: Feb 2022Est. completion: Sep 2025
Phase 1Active Not Recruiting

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Start: Feb 2022Est. completion: Sep 202837 patients
Phase 1Recruiting

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Start: Oct 2021Est. completion: Jul 202414 patients
Phase 1Terminated

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Start: Feb 2020Est. completion: Sep 202616 patients
Phase 1Active Not Recruiting
NCT03389802Pyxis OncologyAPX005M treatment for recurrent or refractory primary malignant CNS tumor patients

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Start: Mar 2018Est. completion: Jun 2026
Phase 1Active Not Recruiting

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Start: Dec 2016Est. completion: Feb 202015 patients
Phase 1Completed

A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

Start: Dec 2013Est. completion: Mar 201720 patients
Phase 1Completed

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Start: Apr 2013Est. completion: Jun 2017202 patients
Phase 1Completed

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

Start: Mar 2010Est. completion: Apr 201513 patients
Phase 1Completed
NCT00964730TevaTalampanel

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Start: Oct 2009Est. completion: Feb 2010135 patients
Phase 1Completed
NCT00299962BiogenInterferon-beta

Gene Therapy for Pleural Malignancies

Start: Mar 2006Est. completion: Oct 200917 patients
Phase 1Completed
NCT00031083BiogenInterferon-beta

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Start: Apr 2002Est. completion: Oct 200312 patients
Phase 1Completed

Expanded Access for KHK2455

N/ANo Longer Available
NCT00645385EisaiMRS Spectroscopy

Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.

Start: Jun 2007Est. completion: Jun 20110
N/AWithdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 3,247 patients
20 companies competing in this space